Health Condition 1: E782- Mixed hyperlipidemia
Conditions
Interventions
Intervention1: RAZEL (Rosuvastatin)
5/10/20/40 mg: Rosuvastatin (5/10/20/40 mg) will be given to patients daily for 12 weeks in the prescribed trial dosages. Use water to administer the prescribed med
Sponsors
JBChemicals Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult (at least 18 years of age) patients of any gender who are already diagnosed with dyslipidemia and those with newly diagnosed/untreated dyslipidemia and are prescribed rosuvastatin or its combination for the treatment of dyslipidemia as a primary and secondary prevention of cardiovascular events in the Indian settings. 2. Patients who are willing to provide written informed consent to share information.
Exclusion criteria
Exclusion criteria: 1. Pregnant women and subjects/LAR who are unable or refused to provide consent will be excluded from the study. Patients having incomplete data will be excluded from the study. 2. The study did not direct the treatment plans which were entirely at the discretion of the physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment pattern of RAZEL (Rosuvastatin) & its combination – Prescribed for dyslipidemia patients as primary prevention or secondary prevention, Duration of Therapy, Concomitant disease (comorbidity), concomitant medications.Timepoint: Baseline, 3 months (12 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Total CholesterolTimepoint: Baseline, 3 months (12 weeks);Change in HDL-CholesterolTimepoint: Baseline, 3 months (12 weeks);change in LDL-CholesterolTimepoint: Baseline, 3 months (12 weeks);Change in TriglycerideTimepoint: Baseline, 3 months (12 weeks);change in VLDL-CholesterolTimepoint: Baseline, 3 months (12 weeks);Global Assessment for Efficacy & SafetyTimepoint: Baseline, 3 months (12 weeks) | — |
Countries
India
Contacts
Public ContactDr Kapil Mehta
J.B.Chemicals & Pharmaceuticals Ltd.
Outcome results
None listed